Alex Brill Featured in Axios
“Made in America” is often “in conflict with an affordability agenda,” said American Enterprise Institute senior fellow Alex Brill, and tradeoffs may be needed with the source of “safe, well-manufactured” drugs.
‘Facing the Future’: Alex Brill discusses tax code and budget challenges
In a recent episode of The Concord Coalition’s Facing the Future podcast, Alex Brill discussed with host, Bob Bixby, the evolving landscape of U.S. tax policy and what it signals for the federal budget—and investors.
2026 Portman Center Symposium: Building an Achievable Fiscal Policy
Alex Brill moderated a discussion of how US legislators can develop successful fiscal policy, featuring Carolyn Bourdeaux and Rob Portman. This conversation was a part of the Portman Center’s 2026 Symposium “Securing Our Fiscal Future: Developing Solutions to Tackle America’s Debt and Deficit.”
FDA Continues to Expedite Biosimilar Development
Following its move in October to eliminate comparative efficacy studies for biosimilars in development, last week the FDA made further strides to streamline the biosimilar approval process in the United States.
Diminishing Returns from the Government’s Drug Negotiation Program
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced the next 15 drugs that will be subject to government price negotiations.
- Alex Brill Featured in Axios
- The Disparate State Impacts and Enormous Cost of a Gas Tax Holiday
- ‘Facing the Future’: Alex Brill discusses tax code and budget challenges
- 2026 Portman Center Symposium: Building an Achievable Fiscal Policy
- Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
